Adverse event# | Ivacaftor¶ | Placebo+ |
Headache | 26 (24) | 17 (16) |
Oropharyngeal pain | 24 (22) | 19 (18) |
Upper respiratory tract infection | 24 (22) | 14 (14) |
Nasal congestion | 22 (20) | 16 (15) |
Abdominal pain | 17 (16) | 13 (13) |
Nasopharyngitis | 16 (15) | 12 (12) |
Diarrohea | 14 (13) | 10 (10) |
Rash | 14 (13) | 7 (7) |
Nausea | 13 (12) | 11 (11) |
Dizziness | 10 (9) | 1 (1) |
Data are presented as n (%). No significant signals were identified through to week 48. #: occurring more commonly (≥8%) in ivacaftor-treated subjects; ¶: n=109; +: n=104.